S&R Foundation Announces 2018 Washington Award Winners

S&R Foundation Announces 2018 Washington Award Winners Press Release from PRNEWSWIRE has been published today, Maciej Heyman, .

WASHINGTON, Jan. 30, 2018 /PRNewswire-USNewswire/ — S&R Foundation, a non-profit organization supporting talented individuals with high aspirations in the arts, sciences and social entrepreneurship, today announced the winners of the 2018 S&R Washington Award – including one Grand Prize winner. The five recipients will be honored at the S&R Washington Awards Ceremony in Washington, DC this spring.

“The 2018 winners are a robust group of emerging artists representing diverse art forms. Their immense talent is equally matched by their creative visions and great potential for lasting influence in the fields of dance, visual arts, musical performance and composition,” said Dr. Sachiko Kuno, President and CEO of S&R Foundation. “These winners stood out among an extremely high caliber of applicants for their technical and conceptual capabilities.”

Gabrielle Lamb, Choreographer (Grand-prize Winner)

A native of Savannah, GA, Lamb is based in New York City, where she directs her own company, Pigeonwing Dance. Previously a soloist with Les Grands Ballets Canadiens, she has created choreography for, among others, Hubbard Street Dance Chicago, the Royal Winnipeg Ballet, BalletX, and Jacob’s Pillow.  She has been described by DANCE Magazine as “a dancer of stunning clarity who illuminates the smallest details—qualities she brings to the dances she makes, too.”

Sara Daneshpour, Piano

Daneshpour is the third prizewinner of the 2017 Arthur Rubinstein International Piano Competition, the 2014 prizewinner of the Seoul International Music Competition, and the 2013 American Pianists Association Laureate of the ProLiance Energy Classical Fellowship awardee. She has studied under the direction of Leon Fleisher at the Curtis Institute of Music, Dr. Yoheved Kaplinsky at The Juilliard School and Dr. Oleg Volkov. Since 2015, she has continued to study with Sergei Babayan at the Cleveland Institute of Music.

Alicia Eggert, Visual Arts

Eggert is an interdisciplinary artist whose work focuses on the relationship between language, image and time. Her artwork has been exhibited internationally, at venues such as the CAFA Art Museum in Beijing, the Triennale Design Museum in Milan, and Sculpture By the Sea in Sydney. She has received numerous awards, including artist grants from the Puffin Foundation and the Harpo Foundation. She is currently an Assistant Professor of Studio Art at the University of North Texas.

Yoshie Ueno, Flute

After winning the Japan Music Competition, Ueno has played as a soloist with the Czech Philharmonic Chamber Orchestra, the members of the Berlin Philharmonic Orchestra, and with many Japanese orchestras. She has twice had the honor of performing for the Emperor of Japan. Ueno has released nine albums varying from Western classical to Asian contemporary music. In 2017, she had solo recitals in NYC and Washington, D.C., and is now based in Paris.

Paul Wiancko, Composition

Wiancko is a ground-breaking composer and cellist who has written genre-bending works for the Aizuri Quartet, yMusic, Boston Cello Quartet, and the Grammy-winning Parker Quartet among many others. As a performer, his versatile artistry has led to collaborations with artists ranging from Chick Corea and Jóhann Jóhannsson to Yo-Yo Ma and the Guarneri Quartet. Mr. Wiancko writes and performs regularly with his chamber ensembles Ayane & Paul and Bird’s Eye Trio.

For more information and full biographies of the 2018 S&R Washington Award winners, visit www.SandRFoundation.org. Washington Award winners each receive a $5,000 prize to support their careers, while Grand Prize winners receive an additional $5,000.

Cision View original content:http://www.prnewswire.com/news-releases/sr-foundation-announces-2018-washington-award-winners-300590702.html

SOURCE S&R Foundation

Related Links


Koss Corp. Releases Second Quarter Results

Koss Corp. Releases Second Quarter Results Press Release from GlobeNewsWire has been published today, Karol Rutkowski, .

MILWAUKEE, Jan. 30, 2018 (GLOBE NEWSWIRE) — Koss Corporation (NASDAQ:KOSS), the U.S. based high-fidelity headphone company, has reported its second quarter results for the quarter ended December 31, 2017. 
Sales for the second quarter were $5,883,877, which is a 12.02% decrease from sales of $6,687,797 for the same three month period one year ago.  The three month net loss was $2,937,721, compared to net income of $140,112 for the second quarter last year.  Diluted and basic loss per common share for the quarter was $0.40 compared to income per common share of $0.02 for the three month period one year ago. “With the reduced corporate tax rate in the new tax law, we recorded a significant tax expense to write down deferred tax assets to their future expected value at the new tax rate in addition to increasing the valuation allowance for deferred taxes,” Michael J. Koss Chairman and CEO said today.  “This tax expense was approximately $3 million even though we had income before taxes for both the December quarter and the first six months.”Koss also explained that sales were off for the quarter primarily due to a decline in sales to OEM accounts and a large order to South America last year that was not repeated this year.  Sales to Europe were up with increased sales into Scandinavia.  Mass market sales in the US were higher with better product placement than a year ago.Sales for the six months ended December 31, 2017, decreased 8.3% from $13,036,503 in the same period last year to $11,950,507 in the current year. The six month net loss was $2,920,221 compared to net income of $224,323 for the same period last year. Diluted and basic loss income was $0.40 for the six months ended December 31, 2017 compared to income per common share of $0.03 for the same six month period one year ago.“Sales to OEM customers in Asia accounted for a large portion of the decline in sales for the first six months compared to last year.” Koss continued, “Sales in the US were up slightly due to increased sales in the mass market.”
Koss Corporation markets a complete line of high-fidelity headphones, wireless Bluetooth® speakers, computer headsets, telecommunications headsets, active noise canceling headphones, wireless headphones, and compact disc recordings of American Symphony Orchestras on the Koss Classics® label.
This press release contains forward-looking statements.  These statements relate to future events or our future financial performance.  In some cases, you can identify forward-looking statements by terminology such as “anticipates,” “believes,” “estimates,” “expects,” “intends,” “plans,” “may,” “will,” “should,” “forecasts,” “predicts,” “potential,” “continue,” or the negative of such terms and other comparable terminology.  These statements are based on currently available operating, financial and competitive information and are subject to various risks and uncertainties.  Actual events or results may differ materially.  In evaluating forward-looking statements, you should specifically consider various factors that may cause actual results to vary from those contained in the forward-looking statements, such as general economic conditions, in particular, consumer demand for the Company’s and its customers’ products, competitive and technological developments, foreign currency fluctuations, and costs of operations.  Shareholders, potential investors and other readers are urged to consider these factors carefully in evaluating the forward-looking statements and are cautioned not to place undue reliance on such forward-looking statements.  The forward-looking statements made herein are only made as of the date of this press release and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances or new information.  In addition, such uncertainties and other operational matters are discussed further in the Company’s quarterly and annual filings with the Securities and Exchange Commission.

Michael J. Koss
Chairman & CEO
(414) 964-5000

La Brightline Initiative annonce des collaborations de recherche avec l’Université technique du Danemark, le Teamwork Global Lab de l’Université de Tokyo et le Consortium pour l’excellence en programme d’ingénierie du Massachus…

La Brightline Initiative annonce des collaborations de recherche avec l’Université technique du Danemark, le Teamwork Global Lab de l’Université de Tokyo et le Consortium pour l’excellence en programme d’ingénierie du Massachus... Press Release from BusinessWire.com has been published today, Marcin Frąckiewicz, .


La Brightline Initiative annonce des collaborations de recherche avec l’Université technique du Danemark, le Teamwork Global Lab de l’Université de Tokyo et le Consortium pour l’excellence en programme d’ingénierie du Massachusetts Institute of Technology

La Brightline Initiative a fait part aujourd’hui de collaborations de recherche avec l’Université technique du Danemark (DTU), le Teamwork Global Lab de l’Université de Tokyo (GTL) et le Consortium for Engineering Program Excellence (CEPE) du Massachusetts Institute of Technology (MIT). L’initiative mettra l’accent sur la recherche de pointe et les solutions pour la mise en œuvre de stratégies.

Lancée en début 2017 par le Project Management Institute (PMI), The Boston Consulting Group (BCG) et l’Agile Alliance, la Brightline™ Initiative est une coalition sans but lucratif des plus grandes organisations mondiales, dédiée à aider les dirigeants à combler le fossé coûteux et improductif entre la conception de la stratégie et son exécution. La Brightline Initiative concentre ses activités sur trois domaines clés : Le leadership en réflexion et en pratique, le travail en réseau et le renforcement des capacités.

« À la DTU, nous sommes heureux de nous joindre à la coalition Brightline. C’est le rôle de la DTU de créer des avantages tangibles pour la société. C’est pourquoi, lorsque l’on crée de nouvelles connaissances scientifiques et des technologies, nous mettons aussi l’accent sur la manière de les mettre en œuvre dans les opérations quotidiennes des organisations et à un niveau de système plus général. Par conséquent, nous croyons que nos objectifs et ceux de Brightline concordent très bien », dit Søren Salomo, chef du service d’ingénierie de la gestion de la DTU.

« Nous cherchons à apporter notre contribution pour améliorer la mise en œuvre de la stratégie, en particulier à travers notre recherche sur la façon de mieux gérer les risques et les incertitudes dans les organisations axées sur la technologie », a déclaré Josef Oehmen, professeur adjoint à la DTU .

« La collaboration avec la Brightline Initiative constitue un lieu d’échange unique pour explorer le carrefour où se croisent l’élaboration de la stratégie et de la planification avec les aspects pragmatiques des opérations, l’apprentissage organisationnel et les changements. Nous sommes particulièrement heureux de l’opportunité de développer de nouvelles méthodes de recherche sophistiquées pour découvrir de nouveaux aspects originaux de la façon dont sont prises les décisions et dont elles sont traduites en actions et en résultats, » a déclaré Eric Rebentisch, chercheur associé au MIT.

La stratégie est une chose vivante qui s’adapte. [1] Dans un monde marqué par des perturbations constantes, une organisation doit prendre compte de son écosystème dans la conception et la mise en œuvre de sa stratégie. La collaboration et la communication, la connaissance et les capacités sont les atouts essentiels d’un dirigeant à la stratégie gagnante.

Le Dr Kazuo Hiekata, professeur adjoint à l’Université de Tokyo, a fait remarquer que « l’équipe GTL fait évoluer les méthodes et les outils pour le système des systèmes, afin de faciliter la communication au-delà des frontières. Notre activité commune avec la Brightline Initiative fournira des résultats excellents en recherche et des répercussions importantes pour la société, en connectant les dirigeants et les employés expérimentés par de nouveaux moyens de communication. » Le Dr Kenji Tanaka, professeur associé au projet, a ajouté: « Des industries bien assises comme le secteur de l’énergie sont tenues de changer radicalement leurs formes actuelles de fonctionnement avec l’émergence des nouvelles technologies et des nouveaux services. La stratégie et l’exécution pour les entreprises bien établies devraient être très différents. »

Dai Ike, coordonnateur de la recherche chez GTL et CEO de GPD Japon, a ajouté : « Les entreprises japonaises cherchent une méthodologie avancée et des équipes internationales pour exécuter les projets complexes et variés directement liés à la stratégie d’entreprise. Cependant, en même temps, ces sociétés hésitent à adopter de nouvelles façons de faire des affaires, avant que d’autres entreprises n’y soient parvenues avec succès. Les histoires de réussite de GTL sont exactement ce que les entreprises recherchent. »

Le directeur général de Brightline, Ricardo Vargas, souligne que « Les collaborations avec la DTU, GTL, et les entités de recherche du MIT renforcent la mission de Brightline qui est de combler le fossé entre la conception de la stratégie et son exécution grâce à une recherche de pointe. Les organisations et les dirigeants bénéficieront des meilleures pratiques dans leurs efforts pour améliorer l’exécution de la stratégie, en cette époque d’innovations perturbatrices. La DTU, GTL et les groupes du MIT apportent des perspectives uniques à partir de leurs champs de recherche. Leur expérience et leurs connaissances sur la stratégie apporteront une valeur ajoutée énorme à notre quête collective de réussite dans la gestion de l’initiative stratégique. »

À propos de la Brightline Initiative

La Brightline™ Initiative est une coalition de grandes organisations internationales, destinée à aider les dirigeants à combler le fossé coûteux et improductif entre la conception de la stratégie et son exécution. Brightline fournit aux organisations trois atouts clés visant à améliorer leurs capacités à mettre en œuvre leurs projets stratégiques : Le leadership en réflexion et en pratique, le travail en réseau et le renforcement des capacités. Pour en savoir plus, www.brightline.org.

À propos de l’Université technique du Danemark

L’Université technique du Danemark est à l’avant-garde académique et multidisciplinaire de la technique et des sciences naturelles — avec de nouvelles initiatives dans un certain nombre de disciplines exigeantes de l’ingénierie, entre autres la technologie de l’énergie durable et les sciences de la vie.

Site Web : dtu.dk

À propos du Global Teamwork Lab (GTL) de l’Université de Tokyo

Le Global Teamwork Lab de l’Université de Tokyo (GTL) est un partenariat universitaire et industriel pour la recherche, les ateliers et l’éducation à travers une équipe de travail internationale. La recherche de la GLT se concentre sur les mécanismes et les dynamiques de la performance sous-jacents à la complexité.

Site Web : gtl.k.u-tokyo.ac.jp

1] Economist Intelligence Unit (EIU), “Closing the Gap: Designing and Delivering a Strategy that Works”, 2017.

Le texte du communiqué issu d’une traduction ne doit d’aucune manière être considéré comme officiel. La seule version du communiqué qui fasse foi est celle du communiqué dans sa langue d’origine. La traduction devra toujours être confrontée au texte source, qui fera jurisprudence.

AARP Releases Consumer Insights Survey on Nutrition and Brain Health

AARP Releases Consumer Insights Survey on Nutrition and Brain Health Press Release from PRNEWSWIRE has been published today, Maciej Heyman, .

WASHINGTON, Jan. 30, 2018 /PRNewswire-USNewswire/ — Adults age 40-plus who say they eat healthy foods most of the time are twice as likely to rate their brain health and mental sharpness as “excellent” or “very good” compared to adults who rarely eat a healthy diet (77% vs. 39%), according to a new AARP consumer survey on brain health and nutrition. But only about one-third (35%) of adults surveyed reported eating nutritious and well-balanced meals “most of the time (5-7 days).”

“Maintaining a healthy diet is vital for good brain health and it is unfortunate that not enough people are aware of the risks associated with poor nutrition,” said Sarah Lock, AARP Senior Vice President for Policy, and Global Council on Brain Health (GCBH) Executive Director. “The results from this survey, along with the latest GCBH report on “Brain Food,” show how certain dietary changes can provide a good foundation for improving brain health.”

Key findings from AARP’s 2017 Brain Health and Nutrition Survey:

  • Significantly more adults who ate the recommended daily amount of fruits and vegetables reported better brain health than those that did not. Most adults, however, are not getting the daily recommended servings in all five food groups. Moreover, one-third did not consume the recommended amount in any food group.
  • Nearly nine in 10 adults said they are likely to eat healthier if they knew it would lower the risks of cognitive decline (87%), heart disease (88%), and diabetes (88%).
  • More than 60% of adults age 40 and older said that they would eat more fish, less red meat, and lower their dairy fat intake if they knew it was good for their brain health.
  • Adults ages 40-54 were significantly more likely to cite barriers to healthy eating compared to adults ages 65 and older.

“The most common reasons people gave for not eating healthier included that it was too difficult, too expensive, they weren’t a “healthy foods type” of person, or their family wouldn’t like the taste,” said Lock. “Half of adults said they would be more likely to change their diet if their doctor told them to do it but only 37% said their doctor has spoken to them about their diet.”

New Recommendations on Nutrition’s Role in Brain Health
Long-term healthy eating habits promote good brain health, according to new consensus recommendations released separately today by the GCBH. The new report finds that a plant-based diet rich in fruits and vegetables is associated with better brain health, and eating fish and other seafood seems to benefit cognitive function. However, excessive alcohol, high levels of saturated fats, and high salt intake are all harmful to brain health. A heart-healthy diet is also a brain-healthy diet because high blood pressure, high cholesterol, and diabetes—all common conditions influenced by diet—harm both cardiovascular and cognitive health. And contrary to recent reports, GCBH recommends a healthy portion of skepticism for people who are drinking coffee, tea, and red wine expecting a brain health benefit until more evidence is developed.

The 2017 AARP Brain Health and Nutrition Survey can be found here:

Additional Resources

Survey Methodology
The 2017 AARP Brain Health and Nutrition survey was fielded October 25-November 8, 2017. Data were collected using GfK’s online probability-based panel. The final, nationally representative sample included 2,033 adults age 40 and older. The final sample was augmented to include a minimum of 350 African Americans, 350 Hispanics/Latinos, and 200 Asians. The margin of error for the general population is ± 2.7 percentage points.

About AARP
AARP is the nation’s largest nonprofit, nonpartisan organization dedicated to empowering Americans 50 and older to choose how they live as they age. With nearly 38 million members and offices in every state, the District of Columbia, Puerto Rico, and the U.S. Virgin Islands, AARP works to strengthen communities and advocate for what matters most to families with a focus on health security, financial stability and personal fulfillment. AARP also works for individuals in the marketplace by sparking new solutions and allowing carefully chosen, high-quality products and services to carry the AARP name. As a trusted source for news and information, AARP produces the nation’s largest circulation publications, AARP The Magazine and AARP Bulletin. To learn more, visit www.aarp.org or follow @AARP and @AARPadvocates on social media.

Cision View original content with multimedia:http://www.prnewswire.com/news-releases/aarp-releases-consumer-insights-survey-on-nutrition-and-brain-health-300590689.html


First Patient Enrolled in Mallinckrodt Phase 4 Trial of H.P. Acthar® Gel (Repository Corticotropin Injection) for Pulmonary Sarcoidosis

First Patient Enrolled in Mallinckrodt Phase 4 Trial of H.P. Acthar® Gel (Repository Corticotropin Injection) for Pulmonary Sarcoidosis Press Release from PRNEWSWIRE has been published today, Maciej Heyman, .

STAINES-UPON-THAMES, United Kingdom, Jan. 30, 2018 /PRNewswire/ — Mallinckrodt plc (NYSE: MNK), a leading global specialty pharmaceutical company, today confirmed enrollment of the first patient in the company’s Phase 4, multi-center, randomized, double-blind, placebo-controlled pilot study to further assess the efficacy of H.P. Acthar Gel as a therapy option in patients with pulmonary sarcoidosis.

H.P. Acthar Gel is approved by the U.S. Food and Drug Administration (FDA) for the respiratory condition symptomatic sarcoidosis, one of 19 indications.

“I am pleased that the first patient has been enrolled in this important Phase 4 study, the results of which may potentially provide evidence to further support Acthar as a treatment option in appropriate symptomatic sarcoidosis patients,” said Dr. Robert Baughman, M.D., Professor in the Department of Internal Medicine, University of Cincinnati College of Medicine, Cincinnati, Ohio1. “In my experience, a considerable number of sarcoidosis patients can have persistent disease that may not be resolved by first-line treatment.”

“The enrollment of the first patient in this study is an important milestone in our further assessment of Acthar’s efficacy as a treatment option for sarcoidosis patients,” said Tunde Otulana, M.D., Chief Medical Officer at Mallinckrodt. “We believe this exploratory evaluation of the more challenging patients who may still have disease activity after previous therapies can potentially help physicians better understand which individuals may benefit from the drug as a treatment alternative.”

Full study details can be found on clinicaltrials.gov.

About the Trial

The Phase 4 clinical study is titled “Pilot Study to Assess the Efficacy and Safety of H.P. Acthar® Gel in Subjects With Pulmonary Sarcoidosis.” This is a Phase 4, multicenter, randomized, double-blind, placebo-controlled pilot study evaluating the efficacy and safety of H.P. Acthar Gel in the treatment of pulmonary sarcoidosis. All subjects who meet eligibility criteria – which include a requirement to be receiving prednisone treatment – will be randomly assigned to receive either 1mL (80 units) of H.P. Acthar Gel or 1mL of a matching placebo subcutaneously 2 times/week. Subjects will be assigned to treatment in a 1:1 ratio with up to 50 subjects per arm for a total of up to 100 subjects. Subjects who complete the 24-week randomized, double-blind, placebo-controlled treatment period will be eligible to continue in an optional 24-week open-label extension.

Response will be evaluated by Sarcoidosis Treatment Score (STS) with a time frame of baseline to 24 weeks. STS is an exploratory newly developed composite score that combines the results of pulmonary function tests (forced vital capacity; diffusing capacity of the lungs for carbon monoxide), high-resolution computed tomography, quality of life (King’s Sarcoidosis Questionnaire; Fatigue Assessment Scale) and corticosteroid tapering.

Find more information about the trial here on the ClinicalTrials.gov website.

About Symptomatic Sarcoidosis2,3,4

Sarcoidosis is a challenging, yet treatable, rare multisystem disease. In some cases the symptoms may come and go throughout a lifetime. This is referred to as symptomatic sarcoidosis. In people with sarcoidosis the immune system overreacts, forming clumps of cells called granulomas that result in inflammation to the body’s tissues. The disease can impact any organ, but it most often impacts the lungs, lymph nodes, eyes, and skin. Over 90 percent of people with sarcoidosis will suffer lung problems. Concomitant involvement of organs outside of the lungs is common, occurring in as many as half of all sarcoidosis cases.

About H.P. Acthar Gel (repository corticotropin injection)


H.P. Acthar Gel is an injectable drug approved by the FDA for the treatment of 19 indications. Of these, today the majority of Acthar use is in these indications:

  • Treatment during an exacerbation or as maintenance therapy in selected cases of systemic lupus erythematosus
  • Monotherapy for the treatment of infantile spasms in infants and children under 2 years of age
  • The treatment of acute exacerbations of multiple sclerosis in adults. Controlled clinical trials have shown H.P. Acthar Gel to be effective in speeding the resolution of acute exacerbations of multiple sclerosis. However, there is no evidence that it affects the ultimate outcome or natural history of the disease
  • Inducing a diuresis or a remission of proteinuria in nephrotic syndrome without uremia of the idiopathic type or that due to lupus erythematosus
  • Treatment during an exacerbation or as maintenance therapy in selected cases of systemic dermatomyositis (polymyositis)
  • The treatment of symptomatic sarcoidosis
  • Adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy)
  • Treatment of severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: keratitis, iritis, iridocyclitis, diffuse posterior uveitis and choroiditis, optic neuritis, chorioretinitis, anterior segment inflammation



  • Acthar should never be administered intravenously
  • Administration of live or live attenuated vaccines is contraindicated in patients receiving immunosuppressive doses of Acthar
  • Acthar is contraindicated where congenital infections are suspected in infants
  • Acthar is contraindicated in patients with scleroderma, osteoporosis, systemic fungal infections, ocular herpes simplex, recent surgery, history of or the presence of a peptic ulcer, congestive heart failure, uncontrolled hypertension, primary adrenocortical insufficiency, adrenocortical hyperfunction or sensitivity to proteins of porcine origins

Warnings and Precautions

  • The adverse effects of Acthar are related primarily to its steroidogenic effects
  • Acthar may increase susceptibility to new infection or reactivation of latent infections
  • Suppression of the hypothalamic-pituitary-axis (HPA) may occur following prolonged therapy with the potential for adrenal insufficiency after withdrawal of the medication. Adrenal insufficiency may be minimized by tapering of the dose when discontinuing treatment. During recovery of the adrenal gland patients should be protected from the stress (e.g. trauma or surgery) by the use of corticosteroids. Monitor patients for effects of HPA suppression after stopping treatment
  • Cushing’s syndrome may occur during therapy but generally resolves after therapy is stopped. Monitor patients for signs and symptoms
  • Acthar can cause elevation of blood pressure, salt and water retention, and hypokalemia. Blood pressure, sodium and potassium levels may need to be monitored
  • Acthar often acts by masking symptoms of other diseases/disorders. Monitor patients carefully during and for a period following discontinuation of therapy
  • Acthar can cause GI bleeding and gastric ulcer. There is also an increased risk for perforation in patients with certain gastrointestinal disorders. Monitor for signs of bleeding
  • Acthar may be associated with central nervous system effects ranging from euphoria, insomnia, irritability, mood swings, personality changes, and severe depression, and psychosis. Existing conditions may be aggravated
  • Patients with comorbid disease may have that disease worsened. Caution should be used when prescribing Acthar in patients with diabetes and myasthenia gravis
  • Prolonged use of Acthar may produce cataracts, glaucoma and secondary ocular infections. Monitor for signs and symptoms
  • Acthar is immunogenic and prolonged administration of Acthar may increase the risk of hypersensitivity reactions. Neutralizing antibodies with chronic administration may lead to loss of endogenous ACTH activity
  • There is an enhanced effect in patients with hypothyroidism and in those with cirrhosis of the liver
  • Long-term use may have negative effects on growth and physical development in children. Monitor pediatric patients
  • Decrease in bone density may occur. Bone density should be monitored for patients on long-term therapy
  • Pregnancy Class C: Acthar has been shown to have an embryocidal effect and should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus

Adverse Reactions

  • Common adverse reactions for Acthar are similar to those of corticosteroids and include fluid retention, alteration in glucose tolerance, elevation in blood pressure, behavioral and mood changes, increased appetite and weight gain
  • Specific adverse reactions reported in IS clinical trials in infants and children under 2 years of age included: infection, hypertension, irritability, Cushingoid symptoms, constipation, diarrhea, vomiting, pyrexia, weight gain, increased appetite, decreased appetite, nasal congestion, acne, rash, and cardiac hypertrophy. Convulsions were also reported, but these may actually be occurring because some IS patients progress to other forms of seizures and IS sometimes mask other seizures, which become visible once the clinical spasms from IS resolve

Other adverse events reported are included in the full Prescribing Information.

Please see full Prescribing Information.

For parents and caregivers of IS patients, please also see Medication Guide.


Mallinckrodt is a global business that develops, manufactures, markets and distributes specialty pharmaceutical products and therapies. Areas of focus include autoimmune and rare diseases in specialty areas like neurology, rheumatology, nephrology, pulmonology and ophthalmology; immunotherapy and neonatal respiratory critical care therapies; and analgesics. The company’s core strengths include the acquisition and management of highly regulated raw materials and specialized chemistry, formulation and manufacturing capabilities. The company’s Specialty Brands segment includes branded medicines and its Specialty Generics segment includes specialty generic drugs, active pharmaceutical ingredients and external manufacturing. To learn more about Mallinckrodt, visit www.mallinckrodt.com.

Mallinckrodt uses its website as a channel of distribution of important company information, such as press releases, investor presentations and other financial information. It also uses its website to expedite public access to time-critical information regarding the company in advance of or in lieu of distributing a press release or a filing with the U.S. Securities and Exchange Commission (SEC) disclosing the same information. Therefore, investors should look to the Investor Relations page of the website for important and time-critical information. Visitors to the website can also register to receive automatic e-mail and other notifications alerting them when new information is made available on the Investor Relations page of the website.

Investor Relations
Coleman N. Lannum, CFA
Senior Vice President, Investor Strategy and IRO

Daniel J. Speciale, CPA
Director, Investor Relations

Rhonda Sciarra
Senior Communications Manager

Meredith Fischer
Chief Public Affairs Officer

Mallinckrodt, the “M” brandmark and the Mallinckrodt Pharmaceuticals logo are trademarks of a Mallinckrodt company. Other brands are trademarks of a Mallinckrodt company or their respective owners. © 2018 ARDUS/01-13/0118/0002 01/18

1 Dr. Baughman’s association with Mallinckrodt includes research grants support, consulting, and involvement with the speakers’ bureau.

2 Judson MA. The clinical features of sarcoidosis: a comprehensive review. Clin Rev Allerg Immunol. 2015;49:63-78.

3 Baughman RP, Culver DA, Judson MA. A concise review of pulmonary sarcoidosis. Am J Respir Crit Care Med. 2011;183:573-581.

4 Shigemitsu H, Patel HV, Schreiber MP. Extrapulmonary sarcoidosis. In: Judson MA, ed. Pulmonary Sarcoidosis: A Guide for the Practicing Clinician. Vol 17. New York, NY: Springer Science+Business Media; 2014:149-186.

Cision View original content with multimedia:http://www.prnewswire.com/news-releases/first-patient-enrolled-in-mallinckrodt-phase-4-trial-of-hp-acthar-gel-repository-corticotropin-injection-for-pulmonary-sarcoidosis-300590288.html

SOURCE Mallinckrodt plc

Related Links


Fidelity National Financial, Inc. Announces Quarterly Cash Dividend of $0.27

Fidelity National Financial, Inc. Announces Quarterly Cash Dividend of $0.27 Press Release from PRNEWSWIRE has been published today, Maciej Heyman, .

JACKSONVILLE, Fla., Jan. 30, 2018 /PRNewswire/ — Fidelity National Financial, Inc. (NYSE: FNF) today announced that its Board of Directors has declared a quarterly cash dividend of $0.27 per share.  The dividend will be payable March 30, 2018, to stockholders of record as of March 16, 2018.

About Fidelity National Financial, Inc.
Fidelity National Financial, Inc. is a leading provider of title insurance and transaction services to the real estate and mortgage industries.  FNF is the nation’s largest title insurance company through its title insurance underwriters – Fidelity National Title, Chicago Title, Commonwealth Land Title, Alamo Title and National Title of New York – that collectively issue more title insurance policies than any other title company in the United States.  More information about FNF can be found at www.fnf.com.

Forward-Looking Statements
This press release contains forward-looking statements that involve a number of risks and uncertainties. Statements that are not historical facts, including statements regarding our expectations, hopes, intentions or strategies regarding the future are forward-looking statements. Forward-looking statements are based on management’s beliefs, as well as assumptions made by, and information currently available to, management. Because such statements are based on expectations as to future financial and operating results and are not statements of fact, actual results may differ materially from those projected. We undertake no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.  The risks and uncertainties which forward-looking statements are subject to include, but are not limited to: changes in general economic, business and political conditions, including changes in the financial markets; weakness or adverse changes in the level of real estate activity, which may be caused by, among other things, high or increasing interest rates, a limited supply of mortgage funding or a weak U. S. economy; our potential inability to find suitable acquisition candidates, acquisitions in lines of business that will not necessarily be limited to our traditional areas of focus, or difficulties in integrating acquisitions; our dependence on distributions from our title insurance underwriters as a main source of cash flow; significant competition that our operating subsidiaries face; compliance with extensive government regulation of our operating subsidiaries; and other risks detailed in the “Statement Regarding Forward-Looking Information,” “Risk Factors” and other sections of the Company’s Form 10-K and other filings with the Securities and Exchange Commission.


Cision View original content:http://www.prnewswire.com/news-releases/fidelity-national-financial-inc-announces-quarterly-cash-dividend-of-027-300590675.html

SOURCE Fidelity National Financial, Inc.

Related Links


University of California, Irvine Extends 15% Tuition Discount to IEEE Computer Society Members

University of California, Irvine Extends 15% Tuition Discount to IEEE Computer Society Members Press Release from PRNEWSWIRE has been published today, Maciej Heyman, .

LOS ALAMITOS, Calif., Jan. 30, 2018 /PRNewswire-USNewswire/ — IEEE Computer Society announced today that IEEE members will receive a 15% discount on tuition for technical classes at the University of California, Irvine (UCI).

“This is an outstanding opportunity for Computer Society members to take advantage of the excellent courses offered by UCI,” says Jean-Luc Gaudiot, 2017 IEEE Computer Society President, and Professor, Department of Electrical Engineering and Computer Science, The Henry Samueli School of Engineering at UCI.

University of California Irvine (UCI) is ranked among the top 50 universities nationally, and tenth among all public universities by U.S. News and World Report. The Division of Continuing Education (DCE) at UCI has been offering education for adult learners for over half a century. Today UCI offers over 60 convenient online programs with a focus in high job-demand industry sectors.  

UCI’s technical online course topics include:

To view all of the exciting new courses and programs that are of particular interest to IEEE members, visit https://ce.uci.edu/areas/ieee/.

About IEEE Computer Society

IEEE Computer Society, the computing industry’s unmatched source for technology information and career development, offers a comprehensive array of industry-recognized products, services and professional opportunities.  Known as the community for technology leaders, IEEE Computer Society’s vast resources include membership, publications, a renowned digital library, training programs, conferences, and top-trending technology events. Visit www.computer.org for more information on all products and services.

Cision View original content with multimedia:http://www.prnewswire.com/news-releases/university-of-california-irvine-extends-15-tuition-discount-to-ieee-computer-society-members-300590681.html

SOURCE IEEE Computer Society

Related Links


BMO Harris Bank Announces Plans for Investing in Employees and Communities as a Result of Tax Reform

BMO Harris Bank Announces Plans for Investing in Employees and Communities as a Result of Tax Reform Press Release from PRNEWSWIRE has been published today, Maciej Heyman, .

  • Minimum wage raised to $15 per hour, effective immediately
  • Community giving to be increased

CHICAGO and MILWAUKEE, Jan. 30, 2018 /PRNewswire/ – BMO Harris Bank today announced that, following the tax reform package recently signed into law, it is both raising its level of community giving and increasing the minimum wage it pays its employees – effective immediately – to $15.00 per hour.

“We’re pleased to share the benefits of the strong economic conditions, and the effects of the recent tax reform changes, with our employees and communities,” said David Casper, President and CEO, BMO Harris Bank.  “Our success is tied directly to the communities we serve, and we’re proud of the exceptional job our employees do in providing a great customer experience.”

Philanthropic giving and a strong employee giving culture are core values at BMO Harris Bank, which plans on building on its position as a market leader in supporting the communities it serves by increasing its level of community giving by 10% in 2018. BMO Harris Bank gave over $17 million to community groups throughout its U.S. footprint in 2017, emphasizing community and economic development, health and human services, education and the arts.

About BMO Harris Bank
BMO Harris Bank provides a broad range of personal banking products and solutions through nearly 600 branches and fee-free access to over 40,000 ATMs across the United States. BMO Harris Bank’s commercial banking team provides a combination of sector expertise, local knowledge and mid-market focus throughout the U.S. For more information about BMO Harris Bank, go to the company fact sheet. Banking products and services are subject to bank and credit approval. BMO Harris Bank N.A. Member FDIC. BMO Harris Bank is part of BMO Financial Group, a highly diversified financial services provider with total assets of CDN$710 billion (as of October 31, 2017), and more than 45,000 employees.

SOURCE BMO Harris Bank

Tower International to Announce Fourth Quarter 2017 Financial Results

Tower International to Announce Fourth Quarter 2017 Financial Results Press Release from PRNEWSWIRE has been published today, Maciej Heyman, .

LIVONIA, Mich., Jan. 30, 2018 /PRNewswire/ — Tower International, Inc. (NYSE: TOWR), a leading global manufacturer of engineered automotive structural metal components and assemblies,  will report fourth quarter 2017 financial results before the market opens on Tuesday, February 13, 2018, via PR Newswire.  At 11:00 a.m. EST on that date, a conference call is scheduled to discuss the results in further detail, as well as other related matters.

To participate in the conference call:

Oasis Petroleum Inc. Announces Passing of Director Ted Collins, Jr.

Oasis Petroleum Inc. Announces Passing of Director Ted Collins, Jr. Press Release from PRNEWSWIRE has been published today, Maciej Heyman, .

HOUSTON, Jan. 30, 2018 /PRNewswire/ — Oasis Petroleum Inc. (NYSE: OAS) (“Oasis” or the “Company“) announced today that Ted Collins, Jr., a member of the Company’s Board of Directors, passed away unexpectedly on January 28, 2018. Mr. Collins was appointed to the Company’s Board of Directors in February 2011 and served on the Company’s Audit and Nominating and Governance Committees.   

Thomas B. Nusz, Chairman and CEO of Oasis, stated: “We are deeply saddened to announce Ted’s passing. On behalf of the Board of Directors and the entire Oasis team, we want to extend our heartfelt condolences to Ted’s family. Ted was a dear friend, a gentleman, and a valued member of the Oasis family.  We will miss him.”

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. All statements, other than statements of historical facts, included in this press release that address activities, events or developments that the Company expects, believes or anticipates will or may occur in the future are forward-looking statements. Without limiting the generality of the foregoing, forward-looking statements contained in this press release specifically include statements regarding the composition of the board of directors and its committees. These statements are based on certain assumptions made by the Company based on management’s experience and perception of historical trends, current conditions, anticipated future developments and other factors believed to be appropriate. Such statements are subject to a number of assumptions, risks and uncertainties, many of which are beyond the control of the Company, which may cause actual results to differ materially from those implied or expressed by the forward-looking statements. These include, but are not limited to, changes in oil and natural gas prices, weather and environmental conditions, the timing of planned capital expenditures, availability of acquisitions, uncertainties in estimating proved reserves and forecasting production results, operational factors affecting the commencement or maintenance of producing wells, the condition of the capital markets generally, as well as the Company’s ability to access them, the proximity to and capacity of transportation facilities, and uncertainties regarding environmental regulations or litigation and other legal or regulatory developments affecting the Company’s business and other important factors that could cause actual results to differ materially from those projected as described in the Company’s reports filed with the Securities and Exchange Commission.

Any forward-looking statement speaks only as of the date on which such statement is made and the Company undertakes no obligation to correct or update any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by applicable law.

About Oasis Petroleum Inc.

Oasis Petroleum is an independent exploration and production company focused on the acquisition and development of unconventional oil and natural gas resources, primarily operating in the Williston and Delaware Basins.

Cision View original content:http://www.prnewswire.com/news-releases/oasis-petroleum-inc-announces-passing-of-director-ted-collins-jr-300590670.html

SOURCE Oasis Petroleum Inc.

Related Links